• Clinical Trials - Multiple Sclerosis (MS)

    Study Objective Contact
    “Association Between Sodium Intake and Disease Activity in Patients with Relapsing Remitting MS – A Pilot Randomized Controlled Study” [LCID Study Number: 2016-064] The purpose of this study is to determine whether being on a low sodium diet (2000mg per day) can reduce occurrences of MS relapses and disease progression seen on MRI(s) as compared to being on a normal sodium diet (no sodium restrictions) over a one year period in patients with Relapsing Remitting MS (RRMS). Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Ramzi Bechara.
    A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (dimethyl fumarate) when Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) [LCID Study Number: 2014-002] This study is being done to gain a better understanding of the benefits and risks of long term treatment with Tecfidera (dimethyl fumarate) in patients with Multiple Sclerosis (MS). The main purpose of this observational study is to collect information on any side effects that may occur in patients taking Tecfidera. Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Ramzi Bechara.
    A Multicenter, Observational, Open-Label, Single- Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients [LCID Study Number: 2012-001] Purpose: An observational study to determine which questionnaires and tests predict disease-free states for patients who are using Tysabri to treat early stages of Multiple Sclerosis. For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Multiple_Sclerosis_Trials.aspx Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Ramzi Bechara.
    An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who Have had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment [LCID Study Number: 2016-026] The purpose of this study is to see if ocrelizumab (study drug) is effective in treating Relapsing Remitting Multiple Sclerosis (RRMS) in patients who have previously tried other adequate disease-modifying treatments without response or with a suboptimal response. Ocrelizumab is an experimental drug and is not FDA approved. Patients in this study would receive an infusion of Ocrelizumab every 24 weeks for up to 96 total weeks. Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Ramzi Bechara.